The stock of Aduro BioTech Inc (NASDAQ:ADRO) is a huge mover today! About 132,268 shares traded hands. Aduro BioTech Inc (NASDAQ:ADRO) has declined 19.05% since March 3, 2016 and is downtrending. It has underperformed by 27.39% the S&P500.
The move comes after 7 months negative chart setup for the $859.01M company. It was reported on Oct, 6 by Barchart.com. We have $12.12 PT which if reached, will make NASDAQ:ADRO worth $42.95M less.
Analysts await Aduro BioTech Inc (NASDAQ:ADRO) to report earnings on November, 28. They expect $-0.49 earnings per share, down 5,000.00% or $0.50 from last year’s $0.01 per share. After $0.03 actual earnings per share reported by Aduro BioTech Inc for the previous quarter, Wall Street now forecasts -1,733.33% negative EPS growth.
Aduro BioTech Inc (NASDAQ:ADRO) Ratings Coverage
Out of 6 analysts covering Aduro Biotech (NASDAQ:ADRO), 3 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 50% are positive. Aduro Biotech has been the topic of 9 analyst reports since August 19, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by FBR Capital given on Tuesday, May 17. The rating was maintained by TH Capital on Tuesday, November 24 with “Buy”. The stock of Aduro BioTech Inc (NASDAQ:ADRO) has “Hold” rating given on Thursday, September 3 by Zacks. The rating was maintained by Roth Capital on Tuesday, November 24 with “Buy”. Oppenheimer initiated Aduro BioTech Inc (NASDAQ:ADRO) rating on Tuesday, October 20. Oppenheimer has “Outperform” rating and $30 price target. Bank of America downgraded the stock to “Underperform” rating in Tuesday, March 15 report. As per Thursday, August 27, the company rating was maintained by Roth Capital. The firm has “” rating by Leerink Swann given on Wednesday, August 19. The firm earned “Perform” rating on Tuesday, December 1 by Oppenheimer.
According to Zacks Investment Research, “Aduro Biotech, Inc. is an immunotherapy company. The Company develops technology and vaccines for the treatment of cancer and mesothelin-expressing tumors. Its product pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX which are in different clinical trial. Aduro Biotech, Inc. is based in BERKELEY, United States.”
More notable recent Aduro BioTech Inc (NASDAQ:ADRO) news were published by: Globenewswire.com which released: “Aduro Biotech Announces New Corporate Offices and Laboratory Space” on September 01, 2016, also Fool.com with their article: “Why Aduro Biotech Is Crashing Today” published on November 24, 2015, Marketwatch.com published: “Aduro Biotech gains on BioNovion acquisition” on September 24, 2015. More interesting news about Aduro BioTech Inc (NASDAQ:ADRO) were released by: Fool.com and their article: “Why a Mid-Stage Trial Is Causing Aduro Biotech to Tumble 22% Today” published on May 16, 2016 as well as Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: May 16, 2016.
ADRO Company Profile
Aduro Biotech, Inc., incorporated on May 5, 2011, is a clinical-stage immunotherapy company. The Firm is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Firm has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. The Company’s LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, LADD technology platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. The Company’s STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. The Company’s B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.